依达拉奉与奥拉西坦联合治疗急性脑梗死的临床研究.doc

依达拉奉与奥拉西坦联合治疗急性脑梗死的临床研究
[摘要] 目的 探讨依达拉奉联合奥拉西坦对急性脑梗死患者的疗效及对血清炎性因子与氧化应激指标的影响。方法 选取我院2015年1月~2017年1月收治的急性脑梗死患者104例为研究对er treatment, and the difference was statistically significant (P<). There was no significant difference in the levels of malondialdehyde and superoxide dismutase between the two groups before treatment(P>). After treatment, the level of malondialdehyde in the observation group was significantly lower than that in the control group, and the level of superoxide dismutase in the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<). Conclusion Edaravone combined with oxiracetam can further reduce brain damage and promote the recovery of nerve function, so it is worthy of clinical promotion. [Key words] Edaravone; Oxiracetam; Acute cerebral infarction; Clinical efficacy; Serum inflammatory factor; Oxidative stress index
脑梗死是缺血性脑卒中的简称,是因为各种原因导致局部脑组织缺血,致使其坏死而发生的相应神经功能缺失[1]。急性脑梗死为突发的脑血管闭塞,其病情严重、发展快、致残率高、死亡率高[2],若不及时给予有效治疗,会严重威胁患者的生命安全,所以及早诊断、及时治疗很有必要[3]。虽然及时溶栓能有效改善患者的预后,但大多患者就医不及时,再加上有的医院医疗水平不够,所以很多患者得不到及时溶栓[4],因此,该病的主要治疗手段还是内科保守治疗。依达拉奉与奥拉西坦均是针对脑血管病的治疗药物,但是两者联合应用在脑梗死患者中的应用研究不够深入,基于此本研究就探讨依达拉奉联合奥拉西坦的治疗效果,现报道如下。
1 资料与方法
一般资料
選取我院2015年1月~2017年1月收治的急性脑梗死患者104例为研究对象,均经临床检查确诊,符合《中国急性期缺血性脑卒中诊治指南》诊断标准,根据不同治疗方法分为两组,对照组(n=52)给予奥拉西坦治疗,其中男32例,女20例;年龄51~78岁,平均(±